Nathaniel F. Watson, MD, MSc
Data suggest that pitolisant, a histamine 3-receptor antagonist/inverse agonist under development for narcolepsy treatment, showed limited abuse potential and other benefits, according to findings presented at SLEEP.
A review in Nature of Science and Sleep indicated that medications currently available to treat either the excessive daytime sleepiness that plagues patients with narcolepsy; cataplexy alone; or excessive daytime sleepiness and cataplexy have abuse, adherence and tolerability concerns.
No commercial support for this activity.
Search Healio's robust listing of national and international medical meetings.
Tell us what you think about Healio.com »
Get the latest news and education delivered to your inbox
©2019 Healio All Rights Reserved.